Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age

Pediatric Infectious Disease Journal

Volumn 17, Issue 11, 1998, Pages 1026-1033

  Carlsson, Rose Marie ^a   Claesson, Bo A ^a   Selstam, Urban ^b   Fagerlund, Eva ^b   Granström, Marta ^c   Blondeau, Christine ^d   Hoffenbach, Agnès ^d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Pediatrics ^*  (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Pasteur Merieux Connaught (PMC)   (France)

Author keywords

Acellular pertussis; Age schedule; Combined; Diphtheria tetanus toxoid; Haemophilus influenzae type b conjugate; Inactivated poliovirus; Infant; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; POLIOMYELITIS VACCINE;

ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DOSE TIME EFFECT RELATION; EDEMA; ERYTHEMA; FEMALE; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFANT; INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEDEN; TETANUS; VACCINATION;

EID: 0031738785     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199811000-00013     Document Type: Article

References (31)

1. International Symposium on Pertussis Vaccine Trials, Rome, October 30 to November 1, 1995: trial synopses. Rome: Instituto Superiore di Sanità, 1995.
2. Granström M. The history of pertussis vaccination: from whole-cell to subunit vaccines. In: Plotkin S, Fantini B, eds. Vaccinia, vaccination and vaccinology: Jenner, Pasteur and their successors, Paris: Elsevier, 1996:107-14.
3. Eskola J, Ölander RM, Hovi T, Litmanen L, Peltola S, Käyhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996; 348:1688-92.
4. Pichichero M, Latiolais T, Bernstein D, et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four-and six-month-old infants. Pediatr Infect Dis J 1997;16: 863-70.
5. Carlsson RM, Claesson BA, Iwarson S, Lagergård T, Käyhty H. Antibodies against Haemophilus influenzae type b and tetanus in infants after subcutaneous vaccination with PRP-T/diphtheria, or PRP-OMP/diphtheria-tetanus vaccines. Pediatr Infect Dis J 1994;13:27-33.
6. Carlsson RM, Claesson BA, Iwarson S, Selstam U. Studies on a Hib conjugate vaccine (PRP-T); the effects of coadministered tetanus toxoid vaccine, combined administration with injectable polio vaccine, and administration route [Abstract G-74]. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17 to 20, 1995. Washington, DC: American Society for Microbiology, 1995.
7. Bizzini B. Tetanus. In: Germanier R, ed. Bacterial vaccines. Orlando, FL: Academic, 1984:37-68.
8. Manclark CR, Meade BD, Burstyn DB. Serological response to Bordetella pertussis. In: Rose NR, Friedman H, Fahey JL, eds. Manual of clinical laboratory immunology. 3rd ed. Washington, DC: American Society for Microbiology, 1986:388-94.
9. Albrecht P, van Steenis G, van Wezel AL, Salk J. Standardization of poliovirus neutralizing antibody tests. Rev Infect Dis 1984;6:S540-4.
10. Kuo JSC, Monji N, Schwalbe RS, et al. A radioactive antigen-binding assay for the measurement of antibody to Haemophilus influenzae type b capsular polysaccharide. J Immunol Methods 1981;43:35-47.
11. Miyamura K, Nishio S, Ito A, Murata R, Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using Vero cells: I. Studies on factors affecting the toxin and antitoxin titration. J Biol Stand 1974;2: 189-201.
12. Gillenius P, Jaatmaa E, Askelof P, Granstrom M, Tiru M. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J Biol Stand 1985;13:61-6.
13. Reed GF, Meade BD, Steinhoff MC. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics 1995;96(3 Pt 2):600-3.
14. Trollfors B, Taranger J, Lagergård T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;333:1045-50.
15. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55.
16. Black S, Shinefield H, Bergen R, et al. Safety and immunogenicity of Chiron/Biocine® recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatr Infect Dis J 1997;16:53-8.
17. Decker M, Edwards K, Steinhoff M, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995;96(3 Pt 2):557-66.
18. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341-8.
19. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind clinical trial comparing a 2-component acellular pertussis vaccine to a whole-cell vaccine in Senegal. Vaccine 1997;15:1606-12.
20. Mallet E, Hoffenbach A, Salomon H, et al. Primary immunisation with combined, acellular DTaP-IPV-Act-Hib, vaccine given at 2-3-4 or 2-4-6 months of age [Abstract 19]. Presented at the 14th European Society for Paediatric Infectious Diseases (ESPID), Elsinore, Denmark, June 18 to 21, 1996.
21. Granström M, Olinder-Nielsen AM, Holmblad P, Mark A, Hanngren K. Specific immunoglobulin for treatment of whooping cough. Lancet 1991;338:1230-3.
22. Granström M, Granström G. Serologic correlates in whooping cough. Vaccine 1993;11:445-8.
23. Böttiger M. A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years. Scand J Infect Dis 1987;19:595-601.
24. Edwards K, Meade B, Decker M et al. Comparison of 13 acellular pertussis vaccines: overview and serologic responses. Pediatrics 1995;96(3 Pt 2):548-57.
25. Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997;16:312-22.
26. Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide tetanus protein conjugate vaccine. J Pediatr 1992;121:355-62.
27. Kurikka S, Käyhty H, Saarinen L, Rönnberg P, Eskola J, Mäkelä PH. Comparison of five diferent vaccination schedules with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. J Pediatr 1996;128:524-30.
28. Nøkleby H, Sandbu S, Käyhty H, Ölander RM, Heilmann C. Vaksine mot Haemophilus influenzae type b-antistoffrespons og biverkninger. Tidsskr Nor Laegeforen 1995;115:1604-6.
29. Claesson BA, Schneerson R, Lagergård T, et al. Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age. Pediatr Infect Dis J 1991;10:560-4.
30. Garpenholt Ö, Silfverdal SA, Hugosson S, et al. The impact of Haemophilus influenzae type b vaccination in Sweden. Scand J Infect Dis 1996;28:165-9.
31. Käyhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 1994;22:397-402.